{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T21:42:10Z","timestamp":1782164530495,"version":"3.54.5"},"reference-count":85,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:00:00Z","timestamp":1723334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple clinical trials have reported favorable outcomes after drug-coated balloon therapy for peripheral artery disease in above-the-knee and below-the-knee lesions and in both de novo and in-stent restenosis. However, there are still insufficient data to identify and tackle the risk factors associated with a higher risk of restenosis, which is the primary concern for patients who are treated with an endovascular approach. A modern armamentarium, which includes improved lesion preparation techniques such as plaque modification balloons, mechanical atherectomy, intravascular lithotripsy, and imaging, is crucial for obtaining better long-term clinical outcomes. Moreover, a better understanding of the molecular properties of drug-coated balloons has led to improved devices that could tackle the shortcomings of previous generations. This comprehensive review focuses on drug-coated balloon technology as a tool to treat peripheral artery disease and the effects of the molecular mechanisms involved in preventing vascular restenosis.<\/jats:p>","DOI":"10.3390\/ijms25168749","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:46:36Z","timestamp":1723607196000},"page":"8749","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Benefits and Challenges of Drug-Coated Balloons in Peripheral Artery Disease: From Molecular Mechanisms to Clinical Practice"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-6405","authenticated-orcid":false,"given":"Dan-Alexandru","family":"Tataru","sequence":"first","affiliation":[{"name":"Medical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400006 Cluj-Napoca, Romania"},{"name":"Interventional Cardiology Department, Cluj County Emergency Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin-Leontin","family":"Lazar","sequence":"additional","affiliation":[{"name":"Medical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400006 Cluj-Napoca, Romania"},{"name":"DCB Academy, 20143 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-7690","authenticated-orcid":false,"given":"Horea-Laurentiu","family":"Onea","sequence":"additional","affiliation":[{"name":"Medical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calin","family":"Homorodean","sequence":"additional","affiliation":[{"name":"Medical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400006 Cluj-Napoca, Romania"},{"name":"Interventional Cardiology Department, Cluj County Emergency Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6203-0825","authenticated-orcid":false,"given":"Mihai-Claudiu","family":"Ober","sequence":"additional","affiliation":[{"name":"Interventional Cardiology Department, Cluj County Emergency Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Olinic","sequence":"additional","affiliation":[{"name":"Medical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400006 Cluj-Napoca, Romania"},{"name":"Interventional Cardiology Department, Cluj County Emergency Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3010-5650","authenticated-orcid":false,"given":"Mihail","family":"Spinu","sequence":"additional","affiliation":[{"name":"Medical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400006 Cluj-Napoca, Romania"},{"name":"Interventional Cardiology Department, Cluj County Emergency Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-9375","authenticated-orcid":false,"given":"Dan-Mircea","family":"Olinic","sequence":"additional","affiliation":[{"name":"Medical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy \u201cIuliu Hatieganu\u201d, 400006 Cluj-Napoca, Romania"},{"name":"Interventional Cardiology Department, Cluj County Emergency Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Horv\u00e1th, L., N\u00e9meth, N., Feh\u00e9r, G., K\u00edv\u00e9s, Z., Endrei, D., and Boncz, I. (2022). Epidemiology of Peripheral Artery Disease: Narrative Review. Life, 12.","DOI":"10.3390\/life12071041"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Olinic, M., Lazar, F.-L., Onea, H.-L., Homorodean, C., Ober, M., Tataru, D., Spinu, M., Achim, A., and Olinic, D.-M. (2024). Peripheral Artery Disease Ultrasound Assessment in Predicting the Severity of Coronary Artery Disease. Life, 14.","DOI":"10.3390\/life14030333"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Martelli, E., Enea, I., Zamboni, M., Federici, M., Bracale, U.M., Sangiorgi, G., Martelli, A.R., Messina, T., and Settembrini, A.M. (2023). Focus on the Most Common Paucisymptomatic Vasculopathic Population, from Diagnosis to Secondary Prevention of Complications. Diagnostics, 13.","DOI":"10.20944\/preprints202305.0209.v1"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"T\u0103taru, D.-A., Olinic, M., Homorodean, C., Ober, M.-C., Sp\u00eenu, M., Laz\u0103r, F.-L., Onea, L., and Olinic, D.-M. (2024). Correlation between Ultrasound Peak Systolic Velocity and Angiography for Grading Internal Carotid Artery Stenosis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13020517"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: The European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00270-024-03747-4","article-title":"TCD-17187 Japan Investigators. Twenty-Four-Month Safety and Effectiveness of TCD-17187 Drug-Coated Balloon for Treatment of Atherosclerotic Lesions in Superficial Femoral and Proximal Popliteal Artery","volume":"47","author":"Soga","year":"2024","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.31083\/j.rcm2204138","article-title":"Should paclitaxel be considered an old generation DCB? The limus era","volume":"22","author":"Lazar","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.31083\/j.rcm2301013","article-title":"DCBs as an adjuvant tool to DES for very complex coronary lesions","volume":"23","author":"Chaddad","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/CIRCULATIONAHA.110.936922","article-title":"Drug-coated balloons for the prevention of vascular restenosis","volume":"121","author":"Gray","year":"2010","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clim.2018.06.006","article-title":"Involvement of CD8+ T cell subsets in early response to vascular injury in patients with peripheral artery disease in vivo","volume":"94","author":"Maga","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1600-6143.2011.03473.x","article-title":"Paradoxical aspects of rapamycin immunobiology in transplantation","volume":"11","author":"Ferrer","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00262-008-0586-2","article-title":"Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse","volume":"58","author":"Vicari","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_13","first-page":"4355","article-title":"Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase","volume":"54","author":"Long","year":"1994","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/sj.onc.1204487","article-title":"Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1\/G2 arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxicity","volume":"20","author":"Giannakakou","year":"2001","journal-title":"Oncogene"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jvir.2016.06.036","article-title":"Comparison of Particulate Embolization after Femoral Artery Treatment with IN.PACT Admiral versus Lutonix 035 Paclitaxel-Coated Balloons in Healthy Swine","volume":"27","author":"Kolodgie","year":"2016","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1161\/01.CIR.103.18.2289","article-title":"Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis","volume":"103","author":"Heldman","year":"2001","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jcin.2022.08.004","article-title":"Low-Dose vs High-Dose Paclitaxel-Coated Balloons for Femoropopliteal Lesions: 2-Year Results from the COMPARE Trial","volume":"15","author":"Steiner","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoro-popliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/CIRCULATIONAHA.119.044697","article-title":"Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis","volume":"141","author":"Duval","year":"2020","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/jamacardio.2019.0325","article-title":"Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices","volume":"4","author":"Secemsky","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1093\/eurheartj\/ehz698","article-title":"Mortality after use of paclitaxel-based devices in peripheral arteries: A real-world safety analysis","volume":"41","author":"Freisinger","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.jcin.2020.04.050","article-title":"Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World","volume":"13","author":"Noory","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2020.07.028","article-title":"Possible mechanism of late lumen enlargement after treatment for de novo coronary lesions with drug-coated balloon","volume":"321","author":"Yamamoto","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jcin.2018.03.046","article-title":"1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty","volume":"11","author":"Bisdas","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.4103\/0366-6999.240819","article-title":"Coronary Artery Aneurysm Formation after Drug-Coated Balloon Treatment","volume":"131","author":"Huang","year":"2018","journal-title":"Chin. Med. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jvs.2014.03.291","article-title":"Paclitaxel-coated balloons and aneurysm formation in peripheral vessels","volume":"62","author":"Diamantopoulos","year":"2015","journal-title":"J. Vasc. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijcard.2020.12.061","article-title":"Late lumen enlargement after treatment of de-novo lesions with drug coated balloon catheters\u2014Glagov effect or plaque regression?","volume":"329","author":"Scheller","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/164_2021_553","article-title":"Mechanistic Target of Rapamycin (mTOR) Inhibitors","volume":"272","author":"Wang","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jcin.2018.11.040","article-title":"Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon","volume":"12","author":"Ali","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1160\/TH06-10-0586","article-title":"Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery","volume":"97","author":"Wessely","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/15266028211064816","article-title":"MagicTouch PTA Sirolimus Coated Balloon for Femoropopliteal and Below the Knee Disease: Results From XTOSI Pilot Study Up To 12 Months","volume":"29","author":"Choke","year":"2022","journal-title":"J. Endovasc. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fca-2020-0085","article-title":"The SELUTION SLR\u2122 drug-eluting balloon system for the treatment of symptomatic femoropopliteal lesions","volume":"17","author":"Noory","year":"2021","journal-title":"Future Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/1526602820941811","article-title":"Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions","volume":"27","author":"Zeller","year":"2020","journal-title":"J. Endovasc. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.carrev.2021.04.013","article-title":"Comparison Between Sirolimus- and Paclitaxel-Coated Balloon for Revascularization of Coronary Arteries: The SIRPAC (SIRolimus-PAClitaxel) Study","volume":"28","author":"Cortese","year":"2021","journal-title":"Cardiovasc Revasc Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.phymed.2017.08.010","article-title":"Protective effects of Paeoniflorin against AOPP-induced oxidative injury in HUVECs by blocking the ROS-HIF-1\u03b1\/VEGF pathway","volume":"34","author":"Song","year":"2017","journal-title":"Phytomedicine"},{"key":"ref_36","first-page":"880","article-title":"Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment","volume":"6","author":"Chen","year":"2020","journal-title":"Bioact. Mater."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ccd.25149","article-title":"Italian Society of Interventional Cardiology. Drug-coated balloon treatment of coronary artery disease: A position paper of the Italian Society of Interventional Cardiology","volume":"83","author":"Cortese","year":"2014","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/RLI.0b013e31820577df","article-title":"Dose response to Paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model","volume":"46","author":"Kelsch","year":"2011","journal-title":"Invest. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2016.07.041","article-title":"Local arterial wall drug delivery using balloon catheter system","volume":"238","author":"Tesfamariam","year":"2016","journal-title":"J. Control Release"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e000117","DOI":"10.1136\/openhrt-2014-000117","article-title":"Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: Impact on neointimal proliferation and healing","volume":"6","author":"Granada","year":"2014","journal-title":"Open Heart"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cao, Z., Li, J., Fang, Z., Feierkaiti, Y., Zheng, X., and Jiang, X. (2022). The factors influencing the efficiency of drug-coated balloons. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.947776"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial","volume":"133","author":"Dake","year":"2016","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tummala, S., Amin, A., and Mehta, A. (2020). Infrapopliteal Artery Occlusive Disease: An Overview of Vessel Preparation and Treatment Options. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103321"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ccd.21898","article-title":"OASIS Investigators Orbital atherectomy for infrapopliteal disease: Device concept and outcome data for the OASIS trial","volume":"73","author":"Safian","year":"2009","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/15266028211070968","article-title":"Orbital Atherectomy Prior to Drug-Coated Balloon Angioplasty in Calcified Infrapopliteal Lesions: A Randomized, Multicenter Pilot Study","volume":"29","author":"Zeller","year":"2022","journal-title":"J. Endovasc. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ccd.26349","article-title":"Impact of lesion location on procedural and acute angiographic outcomes in patients with critical limb ischemia treated for peripheral artery disease with orbital atherectomy: A CONFIRM registries subanalysis","volume":"87","author":"Lee","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_47","first-page":"1","article-title":"Coronary calcifications, the Achilles heel in coronary interventions","volume":"20","author":"Dawood","year":"2024","journal-title":"Postepy Kardiol. Interwencyjnej"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ccd.1810220302","article-title":"Acute angiographic and clinical outcome of high speed percutaneous rotational atherectomy (Rotablator)","volume":"22","author":"Dorros","year":"1991","journal-title":"Cathet Cardiovasc. Diagn."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1583\/09-2826.1","article-title":"One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: The multicenter pathway PVD trial","volume":"16","author":"Zeller","year":"2009","journal-title":"J. Endovasc. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.avsg.2010.10.007","article-title":"One-year outcome after percutaneous rotational and aspiration atherectomy in infrainguinal arteries in patient with and without type 2 diabetes mellitus","volume":"25","author":"Sixt","year":"2011","journal-title":"Ann. Vasc. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1583\/05-1780MR.1","article-title":"Midterm outcomes from the TALON Registry: Treating peripherals with SilverHawk: Outcomes collection","volume":"13","author":"Ramaiah","year":"2006","journal-title":"J. Endovasc. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/152660280701400216","article-title":"Two-year results after directional atherectomy of infrapopliteal arteries with the SilverHawk device","volume":"14","author":"Zeller","year":"2007","journal-title":"J. Endovasc. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e004848","DOI":"10.1161\/CIRCINTERVENTIONS.116.004848","article-title":"Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study","volume":"10","author":"Zeller","year":"2017","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/152660280200900509","article-title":"Complex endovascular treatment for critical limb ischemia in poor surgical candidates: A pilot study","volume":"9","author":"Gray","year":"2002","journal-title":"J. Endovasc. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15266028241248333","DOI":"10.1177\/15266028241248333","article-title":"Outcomes and Comparative Analysis of the Initial Results of Standard Balloon Angioplasty Versus Drug-Coated Balloons Alone Versus in Association With Laser-Excimer Atherectomy in the Treatment of Femoropopliteal Artery In-Stent Restenosis (INTACT)","volume":"24","author":"Ducasse","year":"2024","journal-title":"J. Endovasc. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.avsg.2023.12.091","article-title":"Outcomes of Excimer Laser Ablation Combined with Drug-coated Balloon in Atherosclerotic Lesions of the Popliteal Artery","volume":"104","author":"Jiang","year":"2024","journal-title":"Ann. Vasc. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/1526602818783989","article-title":"Safety and feasibility of intravascular lithotripsy for treatment of below-the-knee arterial stenoses","volume":"25","author":"Brodmann","year":"2018","journal-title":"J. Endovasc. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jcin.2021.04.010","article-title":"Disrupt PAD III Investigators. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the randomized Disrupt PAD III trial","volume":"14","author":"Tepe","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"15266028241255622","DOI":"10.1177\/15266028241255622","article-title":"Intravascular Lithotripsy for Treatment of Severely Calcified Common Femoral Artery Disease: Results From the Disrupt PAD III Observational Study","volume":"15","author":"Shammas","year":"2024","journal-title":"J. Endovasc. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ko, Y.K., Lee, S., Ahn, C., Lee, S., Lee, Y., Kim, B., Hong, M., Jang, Y., Kim, T., and Park, H. (2024). Intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease: A clinical trial. Eur. Heart J., ehae372.","DOI":"10.1093\/eurheartj\/ehae372"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e025677","DOI":"10.1161\/JAHA.122.025677","article-title":"Vessel Patency and Associated Factors of Drug-Coated Balloon for Femoropopliteal Lesion","volume":"12","author":"Soga","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/15266028211058683","article-title":"Impact of Baseline and Postprocedural Intravascular Ultrasound Findings on 1-Year Primary Patency After Drug-Coated Balloon Treatment of Femoropopliteal Lesions","volume":"29","author":"Horie","year":"2022","journal-title":"J. Endovasc. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.23736\/S0021-9509.19.10843-9","article-title":"Optical coherence tomography guided directional atherectomy with antirestenotic therapy for femoropopliteal arterial disease","volume":"60","author":"Stavroulakis","year":"2019","journal-title":"J. Cardiovasc. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15266028231223086","DOI":"10.1177\/15266028231223086","article-title":"Impact of a Less Than 50% Residual Stenosis Following Vessel Preparation in Femoropopliteal Drug-Coated Balloon Angioplasty","volume":"9","author":"Tomoi","year":"2024","journal-title":"J. Endovasc. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jcin.2016.04.012","article-title":"Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial","volume":"9","author":"Kinstner","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa0706356","article-title":"Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg","volume":"358","author":"Tepe","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1161\/CIRCULATIONAHA.115.017364","article-title":"Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial","volume":"132","author":"Krankenberg","year":"2015","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1526602815614555","article-title":"Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study","volume":"23","author":"Grotti","year":"2016","journal-title":"J. Endovasc. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.jacc.2012.07.033","article-title":"Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis","volume":"60","author":"Stabile","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/CIRCINTERVENTIONS.112.971630","article-title":"Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: Evidence from the randomized PACIFIER trial","volume":"5","author":"Werk","year":"2012","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1406235","article-title":"Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease","volume":"373","author":"Rosenfield","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1526602814564383","article-title":"Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: Twelve-month results from the BIOLUX P-I randomized trial","volume":"22","author":"Scheinert","year":"2015","journal-title":"J. Endovasc. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","article-title":"Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial","volume":"131","author":"Tepe","year":"2015","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2015.09.063","article-title":"Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA","volume":"66","author":"Laird","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.avsg.2022.09.047","article-title":"Results of New Dual-Drug Coated Balloon Angioplasty versus POBA for Femoropopliteal Lesions","volume":"89","author":"Sallustro","year":"2023","journal-title":"Ann. Vasc. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jacc.2019.04.057","article-title":"Drug-Eluting Balloon Versus Drug-Eluting Stent for Complex Femoropopliteal Arterial Lesions: The DRASTICO Study","volume":"74","author":"Liistro","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.jcin.2015.07.011","article-title":"Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK\u2019S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries)","volume":"8","author":"Zeller","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jacc.2014.06.1198","article-title":"Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial","volume":"64","author":"Zeller","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_79","first-page":"205","article-title":"Drug-Coated vs Uncoated Percutaneous Transluminal Angioplasty in Infrapopliteal Arteries: Six-Month Results of the Lutonix BTK Trial","volume":"31","author":"Mustapha","year":"2019","journal-title":"J. Invasive Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jvir.2019.11.015","article-title":"Risk of Death and Amputation with Use of Paclitaxel-Coated Balloons in the Infrapopliteal Arteries for Treatment of Critical Limb Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"31","author":"Katsanos","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"121","DOI":"10.23736\/S0392-9590.19.04049-5","article-title":"The use of drug-eluting stents in infrapopliteal arteries: An updated systematic review and meta-analysis of randomized trials","volume":"38","author":"Varcoe","year":"2019","journal-title":"Int. Angiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jcin.2023.11.040","article-title":"Below-the-Knee Endovascular Revascularization: A Position Statement","volume":"17","author":"Li","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s13063-024-08219-1","article-title":"Percutaneous intervention versus surgery in the treatment of common femoral artery lesions: Study protocol for the prospective, multi-center, randomized PESTO-CFA trial","volume":"25","author":"Rastan","year":"2024","journal-title":"Trials"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0140-6736(05)67704-5","article-title":"Bypass versus angioplasty in severe ischaemia of the leg (BASIL): Multicentre, randomised controlled trial","volume":"366","author":"Adam","year":"2005","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa2207899","article-title":"Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia","volume":"387","author":"Farber","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8749\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:34:48Z","timestamp":1760110488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,11]]},"references-count":85,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25168749"],"URL":"https:\/\/doi.org\/10.3390\/ijms25168749","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,11]]}}}